Wealth Enhancement Advisory Services’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$424K Sell
57,017
-6,237
-10% -$57.7K ﹤0.01% 2996
2026
Q2
$438K Buy
63,254
+32,507
+106% +$296K ﹤0.01% 2816
2026
Q1
$95.7K Buy
30,747
+24,684
+407% +$390K ﹤0.01% 3325
2025
Q4
$117K Buy
6,063
+634
+12% +$10.7K ﹤0.01% 3402
2025
Q3
$76K Buy
+5,429
New +$93.1K ﹤0.01% 3373

Other funds holding ADMA

Wealth Enhancement Advisory Services's ADMA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its ADMA Biologics (ADMA) stake by 9.9% in Q3 2026, selling an estimated $57.7K and leaving 57,017 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Wealth Enhancement Advisory Services first reported a position in ADMA in Q3 2025 and has held it in 5 quarters since. The position peaked at $438K in Q2 2026. 327 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Wealth Enhancement Advisory Services held 57,017 shares of ADMA Biologics worth $424K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 6,237 ADMA Biologics shares in Q3 2026, an estimated $57.7K.
  • ADMA Biologics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2996 holding.
  • Wealth Enhancement Advisory Services first reported a position in ADMA Biologics in Q3 2025 and has held it in 5 quarters since.
  • Wealth Enhancement Advisory Services's ADMA Biologics position peaked at $438K in Q2 2026.
  • 327 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.